Promise Peptides: from request to review

Reading and care have different jobs.

Promise Peptides currently arranges prescription review through licensed U.S. providers. It is the telehealth platform, rather than the pharmacy preparing a medicine. Juventa supplies the reading and referral; Promise handles requests for care on its own site.

The four options discussed here are NAD+, MOTS-c, sermorelin and GHK-Cu. They share a place in this guide because of the aging questions around them, not because they have equivalent human evidence. A consultation does not change a mouse experiment into a human result, or a changed hormone measurement into a lasting clinical benefit.

Three steps, with a decision in the middle

1. 1

   Begin with the question

   Read the relevant treatment information on Promise Peptides, then submit a request through its own site. The route serves U.S. patients, with options that depend on the state and treatment.

2. 2

   Leave room for a decision

   A licensed U.S. provider at Promise reviews the request and decides whether a prescription fits. Age, interest and a completed request do not establish eligibility.

3. 3

   Understand the preparation

   When prescribed, the medicine is prepared by a licensed U.S. compounding pharmacy. Compounded medicines prepared for these prescriptions are not FDA-approved, and a prescription does not turn an early research finding into an established result.

A request is not a prescription.

Every Promise request receives a licensed U.S. provider’s review. A licensed provider decides whether treatment is suitable for the person. Sending a request does not guarantee a prescription. Not everybody qualifies. A provider’s answer may be that the proposed option does not fit the person or the problem.

An age-related decline does not identify the cause of a personal concern. The clinical question is more specific than “Could this level be higher?” It includes what is being evaluated, what evidence concerns that problem and whether the uncertainties leave a reasonable basis to proceed. A decision against treatment is still a medical decision.

Only patients in the United States can use this Promise care route. Both the state where a patient is located and the treatment being considered affect availability. A product page is a useful starting point for information, but it cannot establish an individual reader’s eligibility or state access.

The pharmacy has a separate role.

Licensed U.S. compounding pharmacies prepare medicines prescribed through Promise. A pharmacy prepares a compounded medicine for a prescription. It is not an FDA-approved finished product, and the FDA has not reviewed each preparation’s safety, effectiveness and quality before marketing.

The FDA’s compounding explanation describes the difference between a pharmacy-prepared medicine and an approved finished product. A prescription is not a substitute for FDA approval. State licensing, an individual review and the preparation’s regulatory status are related parts of access, but they answer different questions.

Sermorelin has a particular history: a former childhood approval, now withdrawn, and a basis for patient-specific compounding that depends on satisfying the relevant conditions. The sermorelin page explains that history. It does not make the current preparation FDA-approved or establish an adult longevity benefit.

Certification is a different kind of credential.

Promise’s LegitScript certification does not give a medicine FDA approval.

It is possible to consider the service route while remaining uncertain about the treatment. That is a reasonable place to be. A provider’s role is to weigh the person and the proposed care, rather than erase unanswered scientific questions with a credential.

Useful questions for a conversation

• What concern is the proposed treatment intended to address?
• Which human evidence involves this compound and this route?
• What would count as a meaningful result, beyond a laboratory number?
• What uncertainties or features of the health history could change the decision?

Nothing in a general guide can establish an individual diagnosis. The comparison is useful background, especially when two product names seem to be answering the same question.

When the question concerns existing care

Questions about an existing Promise request, treatment access or the service’s current process belong with Promise’s own site. Juventa cannot look inside a care request, make a prescribing decision or speak on a pharmacy’s behalf.

The contact page helps separate a reading question from a service question. Personal medical concerns need a licensed provider who can consider the individual circumstances; a page about aging cannot do that work merely by being detailed.